Takeda Pharmaceutical's 1.7 billion yuan antitrust fine illustrates the end of delayed payments and a big compliance test for pharmaceutical companies.

Recently, a ruling by the federal district court in Boston, United States, has plunged Japanese pharmaceutical giant Takeda Pharmaceutical into an unprecedented crisis. Takeda lost the first instance of the "pay-for-delay" antitrust lawsuit, facing a record-high compensation of up to approximately $25 billion. According to the mandatory treble damages rule of the U.S. Sherman Antitrust Act, this fine will have a fatal impact on the company's finances. Almost simultaneously, Takeda also reached a settlement with the U.S. Department of Justice over the antidepressant drug "kickback scandal", paying a fine of $13.67 million. In addition to the pressure of laying off 4,500 employees and the expiration of patents on several key products, the company is experiencing an unprecedented "dark moment". "Pay-for-delay" is not unique to Takeda, but a controversial business arrangement that has long existed in the global pharmaceutical industry. Originator pharmaceutical companies pay generic drug companies to delay market entry, in order to maintain high drug prices and extend exclusive sales periods. This model, on the surface, appears to be patent settlements but in reality, it excludes market competition. This practice is being targeted by antitrust laws in the United States, the European Union, and China. The Takeda case sends a clear signal to all pharmaceutical companies: the old path of relying on monopolies to "lay and win" is no longer viable, and a new era of compliance and innovation has arrived.